JP2023532857A - Ｌａｉｒ－１結合剤及びその使用方法 - Google Patents

Ｌａｉｒ－１結合剤及びその使用方法 Download PDF

Info

Publication number
JP2023532857A
JP2023532857A JP2022579047A JP2022579047A JP2023532857A JP 2023532857 A JP2023532857 A JP 2023532857A JP 2022579047 A JP2022579047 A JP 2022579047A JP 2022579047 A JP2022579047 A JP 2022579047A JP 2023532857 A JP2023532857 A JP 2023532857A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022579047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532857A5 (https=
Inventor
クリスティン クローリー スザンヌ
ファン ビン
チャン リ ベティ
ベンジャミン リベラ リー
ロバート シソンス ジェームス
シトリン ジョナサン
ワン ヤン
ズハオ スアン
Original Assignee
エヌジーエム バイオファーマシューティカルス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エヌジーエム バイオファーマシューティカルス，インコーポレーテッド filed Critical エヌジーエム バイオファーマシューティカルス，インコーポレーテッド
Publication of JP2023532857A publication Critical patent/JP2023532857A/ja
Publication of JP2023532857A5 publication Critical patent/JP2023532857A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022579047A 2020-06-22 2021-06-21 Ｌａｉｒ－１結合剤及びその使用方法 Pending JP2023532857A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063042299P 2020-06-22 2020-06-22
US63/042,299 2020-06-22
US202063122877P 2020-12-08 2020-12-08
US63/122,877 2020-12-08
PCT/US2021/038251 WO2021262597A2 (en) 2020-06-22 2021-06-21 Lair-1-binding agents and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023532857A true JP2023532857A (ja) 2023-08-01
JP2023532857A5 JP2023532857A5 (https=) 2024-06-28

Family

ID=76959074

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579047A Pending JP2023532857A (ja) 2020-06-22 2021-06-21 Ｌａｉｒ－１結合剤及びその使用方法

Country Status (15)

Country Link
US (2) US12240899B2 (https=)
EP (1) EP4168451A2 (https=)
JP (1) JP2023532857A (https=)
KR (1) KR20230039640A (https=)
CN (2) CN116209676A (https=)
AU (1) AU2021296168A1 (https=)
BR (1) BR112022026284A2 (https=)
CA (1) CA3187944A1 (https=)
CL (1) CL2022003684A1 (https=)
CO (1) CO2022018537A2 (https=)
IL (1) IL299245A (https=)
MX (1) MX2022016544A (https=)
PE (1) PE20230839A1 (https=)
TW (1) TW202216768A (https=)
WO (1) WO2021262597A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023122618A1 (en) * 2021-12-21 2023-06-29 Ngm Biopharmaceuticals, Inc. Combinational use of an anti-ilt3 antibody and an anti-lair-1 antibody
WO2023173091A1 (en) * 2022-03-11 2023-09-14 Ngm Biopharmaceuticals, Inc. Osteoclast-associated ig-like receptor (oscar) and methods of use thereof
JP2025515038A (ja) * 2022-05-05 2025-05-13 アムジェン インコーポレイテッド Ｄｌｌ３及びｃｄ３に結合するヘテロ多量体
IL319594A (en) * 2022-09-16 2025-05-01 Lilly Co Eli Anti-human LAIR1 antibodies
WO2024067864A1 (en) * 2022-09-30 2024-04-04 Shanghai Junshi Biosciences Co., Ltd. Anti-lair1 antibodies and their uses
WO2024215782A1 (en) 2023-04-11 2024-10-17 Ngm Biopharmaceuticals, Inc. Methods of treating osteosarcoma using lair1 binding agents
WO2024215787A1 (en) 2023-04-11 2024-10-17 Ngm Biopharmaceuticals, Inc. Methods of treating osteosarcoma using lair1 binding agents and pd-1 antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020513769A (ja) * 2017-01-02 2020-05-21 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 抗ｌａｉｒ１抗体およびその使用

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140076A (en) 1996-12-06 2000-10-31 Schering Corporation Ig superfamily `dlair` receptors expressed in monocytes
ATE456656T1 (de) 1996-12-06 2010-02-15 Schering Corp Isolierte gene aus säuger monozyten und betreffende reagentien
US20030105303A1 (en) 1996-12-06 2003-06-05 Schering Corporation, A New Jersey Corporation Isolated mammalian monocyte cell genes; related reagents
US20070224663A1 (en) 1997-03-07 2007-09-27 Human Genome Sciences, Inc. Human Secreted Proteins
US20030064072A9 (en) 1999-03-12 2003-04-03 Rosen Craig A. Nucleic acids, proteins and antibodies
EP1264598A1 (en) 2001-06-05 2002-12-11 Universitair Medisch Centrum Utrecht Altering an immune response by influencing the interaction of LAIR with its ligand
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20090304686A1 (en) * 2006-03-08 2009-12-10 Universotair Medisch Centrum Utrecht Interfering in activation of an immune cell by influencing interaction of lair and collagen
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
WO2010078580A2 (en) 2009-01-05 2010-07-08 The Johns Hopkins University Immunotherapy for contact dermatitis using co-signal regulation
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
EA201690746A1 (ru) 2013-10-25 2016-12-30 Фармасайкликс Элэлси Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
MX2017002205A (es) 2014-08-19 2017-08-21 Novartis Ag Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
SG11201701520TA (en) 2014-09-16 2017-04-27 Gilead Sciences Inc Solid forms of a toll-like receptor modulator
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
CN108064166A (zh) 2014-10-23 2018-05-22 戊瑞治疗有限公司 Slamf1拮抗剂及其用途
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
US10201606B2 (en) 2014-11-26 2019-02-12 Miltenyi Biotec Gmbh Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
CA2973720A1 (en) 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
HK1256681A1 (zh) 2015-04-06 2019-10-04 President And Fellows Of Harvard College 用於非清髓性预处理的组合物和方法
ES2876974T3 (es) 2015-04-07 2021-11-15 Novartis Ag Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
AU2016249981B2 (en) 2015-04-13 2022-02-17 Five Prime Therapeutics, Inc. Combination therapy for cancer
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3302557B1 (en) 2015-06-01 2024-01-31 MaineHealth Antagonist of collagen for enhancing the therapeutic activity of an immune checkpoint inhibitor in the treatment of melanoma
NZ738406A (en) 2015-06-11 2023-04-28 Bionomics Ltd Pharmaceutical combination of a tubulin polymerization inhibitor with an inhibitor of pd-l1, pd-1, or ctla-4 and uses and compositions thereof
WO2016207402A1 (en) 2015-06-26 2016-12-29 Institute For Research In Biomedicine Proteins comprising a mutated lair-1 fragment and uses thereof
CA2992551A1 (en) 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
AU2016323985B2 (en) 2015-09-17 2022-12-15 Novartis Ag CAR T cell therapies with enhanced efficacy
PT3356413T (pt) 2015-10-01 2022-04-04 Potenza Therapeutics Inc Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
WO2017079669A1 (en) 2015-11-04 2017-05-11 Incyte Corporation Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor
JP7221049B2 (ja) 2015-11-19 2023-02-13 ノバルティス アーゲー レンチウイルス調製物の安定化のための緩衝液
FI3380620T3 (fi) 2015-11-23 2024-08-01 Novartis Ag Optimoituja lentiviruksen siirtovektoreita ja niiden käyttötapoja
RU2018126297A (ru) 2015-12-18 2020-01-22 Новартис Аг Антитела, нацеленные на cd32b, и способы их применения
RU2018127657A (ru) 2015-12-30 2020-01-31 Новартис Аг Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью
US10697972B2 (en) 2016-01-12 2020-06-30 Bioatla, Llc Diagnostics using conditionally active antibodies
MA55746A (fr) 2016-01-21 2022-03-02 Novartis Ag Molécules multispécifiques ciblant cll-1
US10906977B2 (en) 2016-02-18 2021-02-02 Maine Medical Center Research Institute Enhancing the therapeutic activity of immune checkpoint inhibitor
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
CN109715808A (zh) 2016-04-15 2019-05-03 诺华股份有限公司 用于选择性蛋白质表达的组合物和方法
US12297266B2 (en) 2016-04-18 2025-05-13 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
CN109328070A (zh) 2016-05-04 2019-02-12 免疫疫苗技术有限公司 包含两亲化合物、新抗原和疏水载体的疫苗组合物及其使用方法
CN107523545A (zh) 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的杀伤性细胞及其用途
CN107523547A (zh) 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抑制性抗体的car‑t细胞及其用途
ES2914781T3 (es) * 2016-06-30 2022-06-16 Prothena Biosciences Ltd Composiciones para el tratamiento de la amiloidosis
SG11201900344YA (en) 2016-07-15 2019-02-27 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
US12084495B2 (en) 2016-08-03 2024-09-10 Nextcure, Inc. Compositions and methods for modulating LAIR signal transduction
WO2018033135A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
KR20230167769A (ko) 2016-08-26 2023-12-11 베이롤 칼리지 오브 메드신 세포 치료요법을 위한 항상성 활성 사이토킨 수용체
US11203637B2 (en) 2016-08-26 2021-12-21 Beigene, Ltd. Anti-Tim-3 antibodies and use thereof
AU2017325844A1 (en) 2016-09-14 2019-03-07 Gilead Sciences, Inc. SYK inhibitors
WO2018049474A1 (en) 2016-09-16 2018-03-22 Bionomics Limited Antibody and checkpoint inhibitor combination therapy
CN110087730B (zh) 2016-09-27 2023-03-28 百济神州(苏州)生物科技有限公司 使用包含parp抑制剂的组合产品治疗癌症
JP2019532953A (ja) 2016-09-30 2019-11-14 ノバルティス アーゲー 増強された有効性を有する免疫エフェクター細胞治療
EP3315511A1 (en) 2016-10-29 2018-05-02 Miltenyi Biotec GmbH Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens
JP2020500847A (ja) 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー，インク． 癌の処置のための併用免疫療法
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
US10232053B2 (en) 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
CN107573419A (zh) 2017-01-24 2018-01-12 深圳市体内生物医药科技有限公司 一种增强t细胞抗肿瘤活性的核酸分子
ES2912408T3 (es) 2017-01-26 2022-05-25 Novartis Ag Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
EA201991673A1 (ru) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации
WO2018160731A1 (en) 2017-02-28 2018-09-07 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
US20180271996A1 (en) 2017-02-28 2018-09-27 Mersana Therapeutics, Inc. Combination therapies of her2-targeted antibody-drug conjugates
EP3592368A1 (en) 2017-03-08 2020-01-15 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
CN110831619A (zh) 2017-03-22 2020-02-21 诺华股份有限公司 具有增强功效的生物标志和car t细胞疗法
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
US11884738B2 (en) 2017-03-31 2024-01-30 The University Of North Carolina At Chapel Hill Methods and compositions for activation of T cells using nanoparticles conjugated with multiple ligands for binding receptors on T cells
US11571459B2 (en) 2017-04-03 2023-02-07 Oncxerna Therapeutics, Inc. Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
MX2019012295A (es) 2017-04-14 2020-02-07 Tollnine Inc Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
CN110536700A (zh) 2017-04-19 2019-12-03 南加利福尼亚大学 用于治疗癌症的组合物和方法
CA3063563A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Compositions and methods for an improved antitumor immune response
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018215938A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
US20200299400A1 (en) 2017-05-25 2020-09-24 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
JP2020524157A (ja) 2017-06-20 2020-08-13 アンスティテュート キュリー がん併用療法における使用のためのｓｕｖ３９ｈ１ヒストンメチルトランスフェラーゼの阻害剤
MY202018A (en) 2017-07-31 2024-03-29 Trishula Therapeutics Inc Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
US12350312B2 (en) 2017-09-06 2025-07-08 Fred Hutchinson Cancer Center Methods for improving adoptive cell therapy
WO2019057744A1 (en) 2017-09-19 2019-03-28 Institut Curie AROMATIC HYDROCARBON RECEPTOR AGONIST FOR USE IN ASSOCIATION TREATMENT AGAINST CANCER
WO2019077062A1 (en) 2017-10-18 2019-04-25 Vivia Biotech, S.L. C-CELLS ACTIVATED BY BIT
AU2018351050B2 (en) 2017-10-18 2025-09-18 Novartis Ag Compositions and methods for selective protein degradation
US20210069241A1 (en) 2017-10-20 2021-03-11 Fred Hutchinson Cancer Research Center Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
JP7542438B2 (ja) 2017-11-21 2024-08-30 ノバルティス アーゲー 腫瘍関連抗原に対する三重特異性結合分子及びその使用
US20220267403A1 (en) 2017-12-01 2022-08-25 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
SG11202004864TA (en) 2017-12-01 2020-06-29 Seattle Genetics Inc Cd47 antibodies and uses thereof for treating cancer
CN109908176A (zh) 2017-12-12 2019-06-21 科济生物医药（上海）有限公司 免疫效应细胞和辐射联用在治疗肿瘤中的用途
WO2019126366A2 (en) 2017-12-19 2019-06-27 The Johns Hopkins University Baff therapy to promote anti- tumor immunity
EP3684399A1 (en) 2017-12-29 2020-07-29 Cellectis Method for improving production of car t cells
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
AU2019218397A1 (en) 2018-02-12 2020-10-01 Fred Hutchinson Cancer Center Cyclin A1 specific T cell receptors and uses thereof
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
EP3762105A1 (en) 2018-03-06 2021-01-13 Institut Curie Inhibitor of setdb1 histone methyltransferase for use in cancer combination therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020513769A (ja) * 2017-01-02 2020-05-21 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 抗ｌａｉｒ１抗体およびその使用

Also Published As

Publication number Publication date
EP4168451A2 (en) 2023-04-26
BR112022026284A2 (pt) 2023-03-07
WO2021262597A2 (en) 2021-12-30
IL299245A (en) 2023-02-01
CO2022018537A2 (es) 2023-03-07
TW202216768A (zh) 2022-05-01
CN116209676A (zh) 2023-06-02
CN116813777A (zh) 2023-09-29
WO2021262597A9 (en) 2022-06-02
US20250179171A1 (en) 2025-06-05
AU2021296168A1 (en) 2023-02-02
PE20230839A1 (es) 2023-05-19
CL2022003684A1 (es) 2023-07-28
MX2022016544A (es) 2023-04-05
US20220041711A1 (en) 2022-02-10
US12240899B2 (en) 2025-03-04
WO2021262597A3 (en) 2022-02-24
CA3187944A1 (en) 2021-12-30
KR20230039640A (ko) 2023-03-21

Similar Documents

Publication Publication Date Title
US12410251B2 (en) ILT-binding agents and methods of use thereof
US12187796B2 (en) ILT3-binding agents and methods of use thereof
US12240899B2 (en) LAIR-1-binding agents and methods of use thereof
US20180346571A1 (en) Pd-l1-binding agents and uses thereof
US20210198366A1 (en) B7-h7-binding agents and methods of use thereof
WO2023235706A1 (en) Combination therapies using ilt-binding agents and pd-1 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251125